Trius Therapeutics Funding Round

3/24/2008

Venture Equity

$25,342,000

Series B

"The excellent results from our ongoing Phase I trial, including data confirming thepotential for once-daily dosing, prompted us to raise this round of financing earlier thaninitially planned to accelerate the clinical development of TR-701," stated Jeffrey Stein,Ph.D., President and CEO of Trius Therapeutics. "We are encouraged that KPCB hasrecognized our potential and joined our strong investor group. The proceeds from thisfinancing will enable Trius to advance TR-701 through Phase II and into Phase IIIdevelopment, and to continue to invest in our pre-clinical programs."$4.658 million was funded in Q4, 2007, which was also part of this round.

Acquired or Merged

Biopharmaceutical

6310 Nancy Ridge Drive 105
San Diego, CA 92121
USA

Trius Therapeutics is discovering and developing innovative antibacterial drugs for thetreatment of life-threatening infections. The company's lead product candidate, TR-701 isa novel oral and IV oxazolidinone antibiotic with potent activity against Gram positivebacterial pathogens.